deaths (OS)

endometrial cancer endometrial cancer

versus Standard of Care (SoC)
pembrolizumab plus lenvatinib vs. Standard of Care (SoC) 2 -21%

endometrial cancer - (neo)adjuvant (NA) endometrial cancer - (neo)adjuvant (NA)